GENEVA, 15 July 2025–Lenacapavir–a long-acting, six-monthly injectable antiretroviral medicine manufactured by Gilead Sciences–is now recommended by the World Health Organization as an additional HIV ...

A newly approved HIV prevention drug, lenacapavir, is set to be introduced in at least nine countries in early 2026, and Rwanda could be among the first to deploy it, government and World Health ...

The U.S. Senate will begin voting as soon as Tuesday on President Donald Trump's request to slash $9.4 billion in spending on ...

This 2011 electron microscope image made available by the Centers for Disease Control shows HIV virions. On Wednesday, Sept.

New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck’s once-monthly ...

The World Health Organization has approved the rollout of an injectable HIV preventive drug; Lenacapavir or LEN. The National ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

In the mid-1990s, my then-husband passed away from complications of HIV/AIDS. From the time he was diagnosed until he died, all of us, friends and family, but most of all, him, knew how it would end.

The proposed cuts have caused concerns among some Senate Republicans, including Utah Sen. John Curtis, who may consider ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection.

Integrating HIV and sexual health care is essential for improving outcomes, but global stigma, funding cuts—especially the defunding of USAID—and structural barriers like limited access and political ...